At follow-up around 72 weeks, what degree of noninvasive-test nonresponse would prompt you to stop a GLP-1 receptor agonist prescribed specifically for MASH (even if weight and aminotransferases improve), and what objective criteria do you use in the absence of validated futility rules?

When using GLP-1 as liver-directed pharmacotherapy for the treatment of MASH, liver-related endpoints to assess therapeutic efficacy include >/= 30% relative reduction in MRI-PDFF, decrease in ALT >/= 20%, decrease in VCTE >/= 30%, or MRE-LSM >/=20%. Refer to AASLD Guidance for use of semaglutide fo...